Nicotinamide riboside for Sleeping Quality

Phase-Based Progress Estimates
University at Buffalo State University of New York, Buffalo, NY
Sleeping Quality+2 More
Nicotinamide riboside - DietarySupplement
All Sexes
What conditions do you have?

Study Summary

Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinamide riboside (NR), a form of vitamin B3 may increase the expression of brain-derived neurotrophic factor. This study proposes to examine the benefits of NR supplementation on sleep and cognitive function in older adults with comprehensive subjective and objective measures and to explore its impacts on serum brain-derived neurotrophic factor.

Eligible Conditions

  • Sleeping Quality
  • Cognitive Impairment (CI)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Change from baseline to endpoint at 12 weeks

Week 12
Cognitive function
Sleep Quality Assessment

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Experimental Treatment
Non-Treatment Group

50 Total Participants · 2 Treatment Groups

Primary Treatment: Nicotinamide riboside · Has Placebo Group · N/A

Experimental Group · 1 Intervention: Nicotinamide riboside · Intervention Types: DietarySupplement
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: DietarySupplement
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
Completed Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: change from baseline to endpoint at 12 weeks
Closest Location: University at Buffalo State University of New York · Buffalo, NY
Photo of new york 1Photo of new york 2Photo of new york 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Sleeping Quality
0 CompletedClinical Trials

Who is running the clinical trial?

State University of New York at BuffaloLead Sponsor
208 Previous Clinical Trials
44,190 Total Patients Enrolled

Eligibility Criteria

Age 65+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.